Indications, complications, and management of inferior vena cava filters: The Experience in 952 Patients at an academic hospital with a level I trauma center

JAMA Internal Medicine

Volumn 173, Issue 7, 2013, Pages 513-517

  Sarosiek, Shayna ^a   Crowther, Mark ^b   Sloan, J Mark ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; BLUNT TRAUMA; BRAIN HEMORRHAGE; DEATH; DEMOGRAPHY; DEVICE REMOVAL; DRUG DOSE REGIMEN; FEMALE; FOLLOW UP; HUMAN; INFERIOR CAVA VEIN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OUTCOME ASSESSMENT; PENETRATING TRAUMA; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; THORAX PAIN; THROMBOSIS PREVENTION; TREATMENT INDICATION; VEIN THROMBOSIS; VENA CAVA FILTER; VENOUS THROMBOEMBOLISM;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; CHILD; CHILD, PRESCHOOL; DEVICE REMOVAL; FEMALE; FOLLOW-UP STUDIES; HOSPITALS, UNIVERSITY; HUMANS; INFANT; MALE; MEDICAL RECORDS; MIDDLE AGED; PULMONARY EMBOLISM; RETROSPECTIVE STUDIES; VENA CAVA FILTERS; VENOUS THROMBOEMBOLISM;

EID: 84876015845     PISSN: 21686106     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamainternmed.2013.343     Document Type: Article

References (23)

1. Heit JA, Cohen AT, Anderson FA; VTE Impact Assessment Group. Estimated annual number of incident and recurrent, non-fatal and fatal venous thromboembolism (VTE) events in the US. ASH Annu Meeting Abstracts. 2005;106(11):910.
2. Tapson VF. Acute pulmonary embolism. N Engl J Med. 2008;358(10):1037- 1052.
3. Trousseau A. Painful white swelling. Clin Med Hotel Dieu Paris. 1865;3(2):654-712.
4. Becker DM, Philbrick JT, Selby JB. Inferior vena cava filters: indications, safety, effectiveness. Arch Intern Med. 1992;152(10):1985-1994.
5. Stein PD, Kayali F, Olson RE. Twenty-one-year trends in the use of inferior vena cava filters. Arch Intern Med. 2004;164(14):1541-1545.
6. Decousus H, Leizorovicz A, Parent F, et al; Prévention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. N Engl J Med. 1998;338(7):409-415.
7. Smouse B, Johar A. Is market growth of vena cava filters justified? a review of indications, use, and market analysis. Endovasc Today. February 2010:74-77.
8. Guyatt GH, Akl EA, Crowther M, Gutterman DD, Schuünemann HJ; American College of Chest Physicians Antithrombotic Therapy and Prevention of Thrombosis Panel. Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines [published correction appears in Chest. 2012;141(4): 1129]. Chest. 2012;141(2) (suppl):7S-47S.
9. Kaufman JA, Kinney TB, Streiff MB, et al. Guidelines for the use of retrievable and convertible vena cava filters: report from the Society of Interventional Radiology multidisciplinary consensus conference. J Vasc Interv Radiol. 2006;17(3):449-459.
10. Geerts WH, Bergqvist D, Pineo GF, et al; American College of Chest Physicians. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6) (suppl):381S-453S.
11. Angel LF, Tapson V, Galgon RE, Restrepo MI, Kaufman J. Systematic review of the use of retrievable inferior vena cava filters. J Vasc Interv Radiol. 2011;22(11):1522-1530.e3. http://www.jvir.org/article/S1051-0443 (11) 01242-5/abstract. Accessed January 31, 2013.
12. Tam MD, Spain J, Lieber M, Geisinger M, Sands MJ, Wang W. Fracture and distant migration of the Bard Recovery filter: a retrospective review of 363 implantations for potentially life-threatening complications. J Vasc Interv Radiol. 2012;23(2):199-205.e1. http://www.jvir.org/article/S1051-0443 (11) 01426-6/abstract. Accessed January 31, 2013.
13. Zhou D, Spain J, Moon E, Mclennan G, Sands MJ, Wang W. Retrospective review of 120 Celect inferior vena cava filter retrievals: experience at a single institution. J Vasc Interv Radiol. 2012;23(12):1557-1563.
14. Nicholson W, Nicholson WJ, Tolerico P, et al. Prevalence of fracture and fragment embolization of Bard retrievable vena cava filters and clinical implications including cardiac perforation and tamponade. Arch Intern Med. 2010;170(20):1827-1831.
15. Food and Drug Administration Removing retrievable inferior vena cava filters: initial communication. August 9, 2010. http://www.fda.gov/ MedicalDevices/Safety/AlertsandNotices/ucm221676.htm. Accessed February 10, 2012.
16. Ray CE Jr, Mitchell E, Zipser S, Kao EY, Brown CF, Moneta GL. Outcomes with retrievable inferior vena cava filters: a multicenter study. J Vasc Interv Radiol. 2006;17(10):1595-1604.
17. Mission JF, Kerlan RK Jr, Tan JH, Fang MC. Rates and predictors of plans for inferior vena cava filter retrieval in hospitalized patients. J Gen Intern Med. 2010;25(4):321-325.
18. Minocha J, Idakoji I, Riaz A, et al. Improving inferior vena cava filter retrieval rates: impact of a dedicated inferior vena cava filter clinic. J Vasc Interv Radiol. 2010;21(12):1847-1851.
19. G2 Filter System IFUs [package insert]. Tempe AZ: Bard Peripheral Vascular, Inc; October 2009. http://www.bardpv. com/-international/in-prod- g2filter-ifu.php. Accessed November 29, 2011.
20. PREPIC Study Group. Eight-year follow-up of patients with permanent vena cava filters in the prevention of pulmonary embolism: the PREPIC (Prévention du Risque d'Embolie Pulmonaire par Interruption Cave) randomized study. Circulation. 2005;112(3):416-422.
21. Ko SH, Reynolds BR, Nicholas DH, et al. Institutional protocol improves retrievable inferior vena cava filter recovery rate. Surgery. 2009;146(4):809-816.
22. Geerts WH, Jay RM, Code KI, et al. A comparison of low-dose heparin with lowmolecularweight heparin as prophylaxis against venous thromboembolism after major trauma. N Engl J Med. 1996;335(10):701-707.
23. Medical MS-DRG 301: Peripheral vascular disorders (weight 0.6679) estimated reimbursement $8, 059 versus Surgical MS DRG-254: Other vascular procedures (weight 1.6609) estimated reimbursement $20, 040. http://www.cms.gov/icd10manual/fullcode-cms/P0002.html. Accessed February 6, 2013.